Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance

Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and
                   Provides Full Year 2013 Revenue Guidance

PR Newswire

SAN DIEGO, Jan. 23, 2013

SAN DIEGO, Jan. 23, 2013 /PRNewswire/ --Cadence Pharmaceuticals, Inc.
(NASDAQ: CADX), a biopharmaceutical company focused on acquiring,
in-licensing, developing and commercializing proprietary products principally
for use in the hospital setting, today announced a preliminary (unaudited)
estimate of net product revenue from sales of OFIRMEV^® (acetaminophen)
injection for the three-months ended December 31, 2012, of approximately $17.1

"We ended 2012 on a high note, with fourth quarter revenues exceeding the
guidance given in our announcement of our third quarter 2012 financial
results," said Ted Schroeder, President and CEO of Cadence. "We believe that
our strategy to increase access to OFIRMEV within the hospital and to build
awareness of the product's utility in multi-modal pain management has resulted
in growing sales, and we look forward to continuing this momentum in 2013."

Revenue Guidance
As of January 23, 2013, Cadence expects that net product revenue from sales of
OFIRMEV for the twelve months ending December 31, 2013, will range from
approximately $94.0 million to $100.0 million.

A more complete discussion of Cadence's financial results for the year ended
December31, 2012, will occur during the Company's regularly scheduled
quarterly conference call.

About OFIRMEV^® (Acetaminophen) Injection
OFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for
intravenous use only), Cadence Pharmaceuticals' proprietary intravenous
formulation of acetaminophen, is indicated for the management of mild to
moderate pain, the management of moderate to severe pain with adjunctive
opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was
based on data from clinical trials in approximately 1,020 adult and 355
pediatric patients. These trials included two studies evaluating the safety
and effectiveness of OFIRMEV in the treatment of pain, and one study
evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for
the treatment of acute pain and fever has not been studied in pediatric
patients less than 2 years of age.

Important Safety Information
Do not exceed the maximum recommended daily dose of acetaminophen.
Administration of acetaminophen by any route in doses higher than recommended
may result in hepatic injury, including the risk of severe hepatotoxicity and
death. OFIRMEV is contraindicated in patients with severe hepatic impairment,
severe active liver disease or with known hypersensitivity to acetaminophen or
to any of the excipients in the formulation. Acetaminophen should be used with
caution in patients with the following conditions: hepatic impairment or
active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia,
or severe renal impairment.OFIRMEV should be administered only as a 15-minute
intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated
with allergy or hypersensitivity occur. Do not use in patients with
acetaminophen allergy. The most common adverse reactions in patients treated
with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients
and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in
pediatric patients. The antipyretic effects of OFIRMEV may mask fever in
patients treated for post-surgical pain.

For more information, please see the complete OFIRMEV Prescribing Information,
available at or

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring,
in-licensing, developing and commercializing proprietary products principally
for use in the hospital setting. The current version of Cadence
Pharmaceuticals' corporate overview may be viewed on the Investors page of under "Events & Presentations" by selecting "Corporate

Forward-Looking Statements
Statements included in this press release and Cadence's conference call that
are not a description of historical facts are forward-looking statements.
Words such as "plans," "believes," "expects," "anticipates," and "will," and
similar expressions, are intended to identify forward-looking statements, and
are based on Cadence's current beliefs and expectations. Such statements
include, without limitation, statements regarding: Cadence's fourth quarter
2012 net product revenue estimate and the company's guidance regarding net
product revenue from sales of OFIRMEV for the twelve months ending December
31, 2013. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Cadence's
actual future results may differ materially from Cadence's current
expectations due to the risks and uncertainties inherent in its business.
These risks include, but are not limited to: Cadence's dependence on the
successful commercialization of OFIRMEV, which is the company's only product;
Cadence's ability to achieve broad market acceptance and generate revenues
from sales of OFIRMEV; Cadence's dependence on its contract manufacturers and
its ability to ensure an adequate and continued supply of OFIRMEV to meet
market demand; Cadence's ability to successfully enforce its marketing
exclusivities and intellectual property rights, and to defend the patents
covering OFIRMEV, including in current patent litigation with the parties that
are seeking to market generic versions of OFIRMEV; the potential that Cadence
may be required to continue patent litigation for substantial lengths of time
or file additional lawsuits to defend its patent rights from challenges by
companies that are seeking to market generic versions of OFIRMEV, and the
substantial costs associated with such lawsuits; the potential introduction of
unauthorized generic competition to OFIRMEV in the event Cadence is
unsuccessful in current or future patent litigation; Cadence's dependence on
its licensors for the maintenance and enforcement of its intellectual property
rights; the potential product liability exposure associated with
pharmaceutical products such as OFIRMEV and other products Cadence may
in-license or acquire; Cadence's ability to fully comply with numerous
federal, state and local laws and regulatory requirements that apply to its
commercial activities; public concern regarding the safety of drug products
such as OFIRMEV, which could result in the implementation by regulatory
agencies of new requirements to include unfavorable information in the
labeling for OFIRMEV; the risk that Cadence may not be able to raise
sufficient capital when needed, or at all; and other risks detailed under
"Risk Factors" and elsewhere in Cadence's periodic reports and other filings
made with the Securities and Exchange Commission from time to time. All
forward-looking statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of Section 21E of
the Private Securities Litigation Reform Act of 1995, and Cadence undertakes
no obligation to revise or update this press release to reflect events or
circumstances after the date hereof.

Cadence^® and OFIRMEV^® are trademarks of Cadence Pharmaceuticals, Inc.

Contact: William R. LaRue           Kelli France
         SVP & Chief Financial Officer Media Relations
         Cadence Pharmaceuticals, Inc.      WCG
         Phone: 858-436-1400           Phone: 415-946-1076

SOURCE Cadence Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.